Translational biomarker strategies and PK/PD modeling for next-gen conjugated oligonucleotides and peptides
03 Sept 2026
Novel Modalities & Discovery
- How can we accurately predict human bio-distribution and organ-specific target engagement from early non-human primate (NHP) or in vitro models?
- What are the most reliable pharmacodynamic (PD) and soluble biomarkers for monitoring target engagement in complex conjugate modalities?
- How are teams leveraging quantitative systems pharmacology (QSP) to set safer, more effective First-In-Human (FIH) dose ranges?
